Two brave doctors, Dr. Wolfgang Wodarg and Dr. Michael Yeadon, have issued a motion for administrative and regulatory action to the European Medicines Agency (EMA) regarding the new mRNA coronavirus vaccines developed by Pfizer/BioNTech.
The doctors petition for regulatory action that requires confirmation of efficacy end points.
The doctors are petitioning the EMA for a stay-of-action, halting the emergency approval of the new vaccines until the companies can correct the study design to ensure covid-19 diagnosis/confirmation of data end points is true, and not based on mere, nonspecific symptoms and false positive high cycle PCR tests.
Doctors Warn That Coronavirus Vaccines Will Cause Autoimmune Issues And Infertility In Women
The doctors warn that the study design for the hasty, phase three clinical trials has produced fraudulent data points which will lead to misleading public health guidelines and future harm to human recipients.
The harm they detailed includes the development of auto-antibodies to polyethylene glycol (PEG) that will not only make the vaccine less effective but also cause allergic reactions and deadly adverse events.
The mRNA nano-particles (active ingredients) are coated with PEG.
Furthermore, the vaccines also contain mNeonGreen, an ingredient with bio-luminescent properties.
Why is this ingredient, taken from marine invertebrates, being used in the vaccines?
Most concerning is the vaccine’s potential to cause female infertility.
The mRNA vaccines are intended to induce an immune response to spike proteins of SARS-CoV-2, but these spike proteins (transcribed for replication within cellular ribosomes) also contain a homologous form of syncytin-1.
This natural protein (syncytin-1) is created from human endogenous retroviruses and is responsible for the placenta development in mammals and humans.
This protein is required for a successful pregnancy, but after covid-19 vaccination, an individual’s immune cells will be trained to attack syncytin-1 (leading to potential miscarriages, birth defects and infertility).
The study designs do not test for mutagenic or reproductive defects, yet the science of the mRNA vaccine shows potential to cause long term autoimmune destruction of the female reproductive system.
Vaccine Study Designs Use False Positive PCR Results On Controls To Boost Vaccine Efficacy Rate
The vaccine study designs do not test if the vaccine reduces severe covid-19 symptoms, including hospital admissions, ICU or death.
The tests are not designed to determine if the vaccine can interrupt virus transmission, either.
The tests are designed to see if the vaccine acts as prophylactic or therapeutic, but uses unreliable tests to manufacture fraudulent end points.
Even if the vaccine was an efficacious prophylactic, it carries risk of injury; administering the vaccine to healthy, uninfected people doesn’t make sense because there are better prophylactic and therapeutic strategies that do reduce actual symptoms if the need arises, preventing complications and death.
The worst part of the study design is that it is based on fraudulent diagnoses of SARS-CoV-2.
The doctors warn that “High cycle thresholds, or Ct values, in RT-qPCR test results have been widely acknowledged to lead to false positives.”
They instruct the vaccine makers to fix the study design to properly confirm infection.
“RT-qPCR-positive test results used to categorize patients as ‘COVID-19 cases’ in the trials and used to qualify the trial’s endpoints should be verified by Sanger sequencing to confirm that the tested samples in fact contain a unique SARS-CoV-2 genomic RNA,” the doctors wrote.
The vaccine makers are using fraudulent false positive diagnosis of covid-19 in the control group to make the vaccine look more efficacious.
Since high cycle PCR tests have been ruled to be 97 percent false positive, the end points collected in the Pfizer/ BioNTech studies could ultimately show that the vaccine is less than 3 percent efficacious, with potential to cause severe and lasting health effects, including but not limited to: infertility of women.
Vaccines have been proposed as one of the strategies for population control. Immunocontraceptive vaccines can be designed to inhibit: (1) production of gametes (sperm and egg); (2) functions of gametes, leading to blocking of fertilization; and (3) gamete outcome (pregnancy). Immunization with gonadotropin‐releasing hormone coupled to different carriers has shown curtailment in the production of sperm with concomitant infertility in various species. Immunization of nonhuman primates and men with ovine follicle stimulating hormone has also resulted in reduced sperm output. Various spermatozoa‐specific proteins such as FA1, PH‐20, LDH‐C4, SP‐10, SP‐17, sp56, SPAG9, and Izumo have been proposed as candidate antigens to develop contraceptive vaccines, which have shown efficacy in inhibiting fertility in different animal models. Immunization with zona pellucida glycoproteins‐based immunogens also results in curtailment of fertility in a variety of species. However, ways to overcome the observed oophoritis associated with zona proteins immunization have yet to be discovered, a necessary step before their proposal for control of human population. Nonetheless, this is a very promising approach to control wildlife animal population. Phase II clinical trials of β‐human chorionic gonadotropin‐based vaccine in women have established the proof of principle that it is possible to inhibit fertility without any untoward side‐effects by vaccination. Further scientific inputs are required to increase the efficacy of contraceptive vaccines and establish their safety beyond doubt, before they can become applicable for control of fertility in humans.Keywords: Fertilization, Hormones, Immunocontraception, Spermatozoa, Vaccine, Zona pellucida
The increasing human population is an important driving anthropogenic factor, among others, responsible for increased atmospheric concentration of greenhouse gases (GHGs). The impact = population × affluence × technology (IPAT) model suggests that increasing population and economic growth in the coming decades will exacerbate GHGs , which may produce disruptive changes in global climate, putting our existence on Earth at stake. Hence, there is an urgent need for commensurate efforts to stabilize human population at a sustainable level. It is estimated that, by 2020, about 1.2 billion people, or 16% of the world’s population, will be entering their child‐bearing years. Furthermore, 90% of those entering reproductive age will be in the developing world, where there is a particularly pressing need for new contraceptives that are cheap, safe, reliable, convenient, reversible, and culturally acceptable. Hence, there is an urgent need for investment in efforts leading to the development of new forms of contraceptive.
In addition to growing concerns about the increasing human population across the globe, effective and humane management of wild and domestic animal populations is becoming a major issue . For example, the elephant population in Africa is increasing at a significant rate. As a consequence of increased urbanization, conflict now exists between overlapping elephant habitats and land use for human habitation. Moreover, in a number of countries around the world, wild animals that act as vectors or reservoirs for disease pose a major risk to both human health and agriculture. Wildlife managers have often used lethal means to control populations; however, growing public concerns over animal welfare issues make such approaches increasingly unacceptable. Immunocontraception for wildlife management is therefore taking on a new perspective, and many agencies charged with such management decisions are turning to fertility control as a potential humane solution for this problem . Immunocontraceptive vaccines entail generating humoral and/or cell‐mediated immune responses against hormones/proteins that are critical to reproduction, interference with the biological function of which will result in blocking of fertility. Contraceptive vaccines may result in either reversible or irreversible inhibition of fertility.Go to:
Targets for the development of immunocontraceptive vaccines
There are multiple points in the reproductive process that can be targeted for immunological intervention to achieve infertility (Fig. (Fig.1).1). These fall into three broad categories: (1) gamete production, (2) gamete function, and (3) gamete outcome. Gonadotropin‐releasing hormone (GnRH) synthesized and secreted by the hypothalamus acts on the pituitary and regulates the production of luteinizing hormone (LH) and follicle stimulating hormone (FSH). LH and FSH, in turn, act on the testes and ovaries, leading to the production of sperm and oocytes, respectively. Neutralization of GnRH, LH or FSH may interfere with the production of gametes and thereby inhibit fertility. Both male (spermatozoon) and female (egg) gametes have unique antigens against which immune response can be elicited, leading to blocking of fertilization. Post fertilization, the embryo synthesizes and secretes human chorionic gonadotropin (hCG), which helps in the rescue of corpus luteum and production of progesterone, which is crucial for establishment and maintenance of pregnancy. Neutralization of hCG by antibodies can interfere in implantation of the blastocyst. In the present review, an attempt is made to discuss the current status of various immunological approaches to contraception, current limitations, and future prospects.
Vaccines for inhibition of gamete production
To inhibit gamete production to lead to blocking of fertility, immunization strategies with respect to GnRH and FSH have been investigated, as summarized below.